Covid: Pfizer sets a date for the arrival of its adapted vaccine at Ómicron

BioNTech and Pfizer updated on Monday the date when they expect the arrival of their vaccine against COVID-19 adapted to the BA.1 and BA.4/5 variants.

This is how BioNTech advanced in the presentation of its financial results for the first half of 2022which includes second-quarter 2022 revenue of €3.2 billion, with net profit of €1.7 billion, as well as first-half 2022 revenue of €9.6 billion euros, with a net profit of 5.4 billion euros.

When will the Pfizer vaccine adapted to Ómicron arrive?

The pharmaceutical company has confirmed that doses against Ómicron will not arrive until October 2022, “in time for the fall recall campaigns”.

It should be recalled that the new Ómicron variants -BA.4 and BA.5- were identified at the start of the year in South Africa and they represent the majority of sequenced cases not only in our country, but also in the world. In recent weeks, there has been an increase in infections and hospitalizations due to the new subvariants.

Specifically, BA.5 is the most contagious variant since is able to evade antibodies generated by vaccination and previous infections.

As reported by CNN, he has three key mutations in its protein that make it more efficient at infecting our cells. Additionally, it also has a mutation in amino acids L452R, F486V, and R493Q, the part of the SARS-CoV-2 Spike protein that vaccines act on.

The genomic mutations of BA.4 and BA.5 compared to their predecessors are so large that Experts are already talking about a new virus: Covid-22very different from the one encountered in 2019.

Benefits of the vaccine

Regarding its vaccine against COVID-19, Pfizer’s forecast is to enter between 13,000 and 17,000 million euros in 2022. This revenue estimate reflects projected revenue related to BioNTech’s share of gross profit from sales of the vaccine in collaborating partner territories, direct sales of the vaccine to customers in BioNTech’s territory, and projected revenue generated from the products. manufactured by BioNTech and sold to collaborating partners.

“In the first half of 2022, we reached milestones, as we have further strengthened our leadership in vaccines, expanded our broad product portfolio and accelerated its maturation. Our COVID-19 product portfolio includes variant-tailored and next-generation vaccine candidates aimed at long-term and broad protection. In oncology, we submitted encouraging data updates for our individualized mRNA cancer vaccine candidate BNT122 in pancreatic cancer and our novel CAR-T cell therapy candidate BNT211 in solid tumors, leading to our first PRIME designation for part of the EMA. We are moving towards preparing for registration trials, as well as delivering our first BioNtainers to Africa, with the aim of providing access to new drugs,” said BioNTech CEO and co-founder Ugur Sahin. .

“With the strong results achieved to date, we believe we are on track to achieve our financial guidance for this year. With our initiatives around variant-appropriate COVID-19 vaccine candidates, we expect demand to increase in our key markets in the fourth quarter of 2022, subject to regulatory approval. We will continue to invest heavily in research and development in 2022 and beyond, and remain focused on advancing our oncology product pipeline, as well as strengthening our leadership in COVID-19 vaccine development. 19. We are driving the potential launch of several innovative products to treat diseases with high unmet medical need over the next three to five years,” added BioNTech CFO Jens Holstein.

Leave a Comment